TY - JOUR T1 - Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA2561 VL - 46 IS - suppl 59 SP - PA2561 AU - Claus Kroegel AU - Martin Foerster AU - Kristin Lerche AU - Maryam Aalamian-Mattheis AU - Janett Happe AU - Anne Moeser AU - Stephanie Korn Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA2561.abstract N2 - Background: OMA is an effective treatment option in SAA. However, little data are available on the long-term-efficacy oft the drug.Objective: To determine the long-term efficacy of OMA in respect to clinical parameters and IgE serum levels.Methods: This was a retrospective, open-label, uncontrolled, multi-center observational study according to the definition of non-interventional studies. 22 non-smoking patients (10 m, 12 f; mean age 47,9 yrs) with SAA were enrolled. Pat were treated with OMA up to for 4 years and total serum IgE levels were assessed at initiation of therapy, after 2-6 ms and 3-5 yrs. Data were recorded on standardized CRFs by the treating physician.Results: The average duration of therapy was 3.5 +/-1.2 (3–7) years. The total serum IgE levels accounted for 307.0 IU/ml (median) at baseline, increased to 816.5 IU/ml after 1 year and decreased to 435.0 IU/ml after 4 yr therapy. Asthma symptoms declined from 95.5% at baseline to 9.1% at the the third yr. Lung function (FEV1; median 70.5% predicted at baseline) did not deteriorate over the treatment period. Physicians' global evaluation of treatment effectiveness (GETE) was denoted 'excellent' or ´good´ in 87, 92, 86, and 77% of the cases after 1 to 4 yrs treatment. The number of Pat with concomitant allergic diseases decreased (atopic dermatitis from 27 to 9%; food allergy from 36 to 27%) after 4-year therapy. No drug-related SADRs were observed.Conclusion: OMA induces and maintains long-term remission in SAA over a period of at least 4 yrs. After the initial increase, serum IgE levels tend to decrease over time. ER -